<DOC>
	<DOCNO>NCT00636922</DOCNO>
	<brief_summary>The main goal study assess safety tolerability RAD001 combination low-dose cytarabine acute myeloid leukemia patient unfit intensive chemotherapy . The secondary goal investigate likely cause drug response failure .</brief_summary>
	<brief_title>Everolimus ( RAD001 ) Elderly Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>A multicentre 2-stage Phase Ib/II trial 5-Azacitidine combine Everolimus AML patient age 60 relapse AML age 18 . The MTD DLT 5-Azacitidine ( 7 dos 9 day ) give monthly combine Everolimus orally 17 day ( day 5-21 ) month ( 1 cycle ) minimum 6 cycle least 2 cycle beyond achievement CR maximum 12 cycle . Everolimus maintenance therapy alone may continue investigator 's discretion either progressive disease dose limit toxicity . Groups 3 patient enter dose level . Dose escalation/stopping rule determine maximum tolerate dose ( MTD ) follow : Number cohort experience DLT day 42 Action 2/3 3/3 No dose escalation . Previous level define MTD 0/3 Dose escalate next level 1/3 Expand cohort 6 patient 1/6 2/6 Dose escalate next level &gt; 2/6 No dose escalation . Previous level define MTD Note dose escalation still indicate high dose level , MTD last dose level . If trial stop first dose , MTD first dose level . In either case , MTD determine trial . Once maximum dose level identify , dose expansion phase continue recruit patient MTD total 40 patient entire study accrue .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Untreated AML patient ( define WHO 2008 criterion ) age 60 relapsed/refractory AML age 18 receive 2 previous line intensive chemotherapy No prior failure achieve least PR Azacitidine Everolimus Provision write informed consent Secondary AML ( include therapyrelated ) include Life expectancy great 3 month relation diseases AML/MDS ECOG performance status 0 3 Electrolyte level ( potassium , calcium ( albuminadjusted ) , magnesium , phosphorous ) within normal limit ( WNL ) easily correctable supplement Adequate hepatic function define bilirubin ≤ 1.5 x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Adequate renal function , serum creatinine ≤ 1.5 x ULN GFR &gt; 30 ml/minute Patients uncontrolled active infection Hydroxyurea cease 48 hour prior study therapy Exclusion Criteria Any serious medical psychiatric condition investigator feel may interfere patient 's ability give inform consent participate procedure evaluation study History major noncompliance medication Evidence CNS leukemia Uncontrolled viral infection know HIV Hepatitis type B C Currently active gastrointestinal disease ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhoea , malabsorption syndrome , small bowel resection ) , disease , prevent patient absorb take oral medication Any concurrent severe and/or uncontrolled medical condition ( eg . acute chronic liver disease , infection , pulmonary disease ) opinion investigator could potentiate unacceptable safety risk jeopardize compliance protocol Males female partner childbearing potential agree use least 2 effective contraceptive method throughout study 6 month follow date last dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Elderly</keyword>
	<keyword>Unfit</keyword>
	<keyword>Everolimus</keyword>
	<keyword>RAD001</keyword>
</DOC>